Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

What is Genetic Engineering?

What is Genetic Engineering?

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Vaccinations

Vaccinations

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changes in macular ganglion cell and retinal nerve fiber layer thickness during recovery from infection with the B.1.1.7 variant of SARS-CoV-2 in previously hospitalized patients with COVID-19 bilateral pneumonia.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2024

Same author

Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF<sup>v600</sup> mutation-positive melanoma receiving adjuvant vemurafenib.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Journal of viral hepatitis·2017

Same author

Comparative studies of cervical spine anterior stabilization systems--Finite element analysis.

Clinical biomechanics (Bristol, Avon)·2016

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Gene-modified cellular vaccines: technologic aspects and clinical problems.

J Mackiewicz¹, A Mackiewicz

¹Department of Cancer Immunology, Poznan University of Medical Sciences, Greater Poland Cancer Center, Poznan, Poland.

Transplantation Proceedings

|October 26, 2010

Summary

Cancer vaccine development is rapidly advancing, with many therapeutic vaccines nearing market approval. Challenges remain in clinical trial design and patient stratification for optimal treatment response.

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8⁺ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Related Experiment Videos

Last Updated: Jun 7, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8⁺ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Area of Science:

Oncology
Immunology
Biotechnology

Background:

The cancer vaccine sector has seen a fourfold increase in activity over the past decade.
Numerous therapeutic cancer vaccines are emerging, with many clinical trials nearing evaluation.

Purpose of the Study:

To address the challenges in developing and evaluating cancer vaccines, particularly whole cell and gene-modified whole cell types.
To highlight the need for standardized characterization and adapted clinical trial designs for cancer immunotherapies.

Main Methods:

Review of current trends in cancer vaccine development and clinical trials.
Discussion of manufacturing, characterization, and standardization challenges for cell-based vaccines.
Analysis of existing clinical trial designs and proposed modifications for active immunotherapy.

Main Results:

Cancer vaccines, especially whole cell types, present unique challenges in product characterization (identity, purity, potency, etc.).
Current clinical trial designs, adapted from chemotherapy, are often unsuitable for cancer immunotherapies.
Development of biomarkers for patient stratification is crucial for personalized cancer vaccine therapy.

Conclusions:

Standardized characterization and adapted clinical trial designs are essential for successful cancer vaccine development.
Biomarker discovery is critical for identifying patients likely to benefit from specific cancer vaccine treatments.
Future research should focus on optimizing trial designs and patient selection for cancer immunotherapy.